Published in J Aging Res on December 30, 2010
Translational research in immune senescence: assessing the relevance of current models. Semin Immunol (2012) 1.00
Lithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cells. Oncotarget (2011) 0.88
Id4 promotes senescence and sensitivity to doxorubicin-induced apoptosis in DU145 prostate cancer cells. Anticancer Res (2013) 0.83
Integrin-linked kinase regulates senescence in an Rb-dependent manner in cancer cell lines. Cell Cycle (2015) 0.79
Tumor regression by phenethyl isothiocyanate involves DDB2. Cancer Biol Ther (2012) 0.79
Disruptive chemicals, senescence and immortality. Carcinogenesis (2015) 0.78
RAC3 more than a nuclear receptor coactivator: a key inhibitor of senescence that is downregulated in aging. Cell Death Dis (2015) 0.77
Mitotic Stress Is an Integral Part of the Oncogene-Induced Senescence Program that Promotes Multinucleation and Cell Cycle Arrest. Cell Rep (2015) 0.76
The hallmarks of cancer. Cell (2000) 113.05
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. Exp Cell Res (1965) 21.61
BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87
Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol (2007) 16.55
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell (1997) 13.34
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell (2005) 12.73
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell (1997) 12.41
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (1993) 12.02
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol (2008) 11.43
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 11.40
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature (2006) 11.18
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Oncogene-induced senescence as an initial barrier in lymphoma development. Nature (2005) 9.16
Intrinsic tumour suppression. Nature (2004) 8.73
Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol (2003) 8.42
Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A (2001) 7.93
The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol (2010) 7.58
A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol (1973) 7.28
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature (2001) 7.06
Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell (1999) 6.98
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76
p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell (1999) 5.93
Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science (1997) 4.97
Inhibition of telomerase limits the growth of human cancer cells. Nat Med (1999) 4.96
Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer (2008) 4.63
Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol (2006) 4.54
Tumor cell senescence in cancer treatment. Cancer Res (2003) 4.15
Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci (2005) 3.96
Glycolytic enzymes can modulate cellular life span. Cancer Res (2005) 3.78
Myc activates telomerase. Genes Dev (1998) 3.74
DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene (2007) 3.67
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature (2001) 3.57
Putting the stress on senescence. Curr Opin Cell Biol (2001) 3.41
Oncogene-induced cell senescence--halting on the road to cancer. N Engl J Med (2006) 3.39
Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood (2005) 3.30
DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res (2002) 3.22
p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol (2000) 3.15
Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol (2000) 3.12
The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res (2006) 3.07
Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev (1999) 3.04
Myc and the cell cycle. Front Biosci (1998) 2.88
The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer (2006) 2.85
Replicative senescence: implications for in vivo aging and tumor suppression. Science (1996) 2.83
Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene (2004) 2.81
Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol (2002) 2.70
A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res (1999) 2.67
p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol (2005) 2.65
The retinoblastoma gene family: cousins with overlapping interests. Trends Genet (1998) 2.59
BRAF(E600) in benign and malignant human tumours. Oncogene (2007) 2.45
Many roads lead to oncogene-induced senescence. Oncogene (2008) 2.43
Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol (1998) 2.42
A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS One (2010) 2.38
Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene (1999) 2.34
Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev (2010) 2.32
Genetic analysis of indefinite division in human cells: identification of four complementation groups. Proc Natl Acad Sci U S A (1988) 2.08
Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res (2006) 2.04
Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene (1999) 2.00
Cellular senescence and cancer treatment. Biochim Biophys Acta (2006) 1.96
DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. Mol Biol Cell (2006) 1.78
Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)-dependent pathways. EMBO J (2000) 1.73
The disparity between human cell senescence in vitro and lifelong replication in vivo. Nat Biotechnol (2002) 1.69
Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem (2002) 1.62
Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol (2007) 1.62
Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood (2001) 1.61
Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate (2003) 1.61
Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol (2005) 1.61
Molecular signature of oncogenic ras-induced senescence. Oncogene (2004) 1.60
DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J (2004) 1.58
p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res (1999) 1.57
The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia (2005) 1.39
Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. Cancer Res (2002) 1.37
Time, telomeres and tumours: is cellular senescence more than an anticancer mechanism? Trends Cell Biol (1995) 1.36
The role of DNA damage repair in aging of adult stem cells. Nucleic Acids Res (2007) 1.35
Aberrant methylation of gene promoters in cancer---concepts, misconcepts, and promise. J Natl Cancer Inst (2000) 1.35
Mice without telomerase: what can they teach us about human cancer? Nat Med (2000) 1.33
Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res (2005) 1.30
Replicative senescence and oxidant-induced premature senescence. Beyond the control of cell cycle checkpoints. Ann N Y Acad Sci (2000) 1.29
Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr Biol (1997) 1.28
Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood (1999) 1.28
Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status. Oncogene (1997) 1.27
Oxygen free radicals in cell senescence: are they signal transducers? Free Radic Res (2006) 1.27
Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence. Oncogene (1996) 1.25
Smurf2 up-regulation activates telomere-dependent senescence. Genes Dev (2004) 1.23
The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. Aging (Albany NY) (2009) 1.19
Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle (2006) 1.17
New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas. Oncol Rep (2006) 1.15
Replicative stress, stem cells and aging. Mech Ageing Dev (2008) 1.14
Cell cycle deregulation: a common motif in cancer. Prog Cell Cycle Res (2003) 1.14
Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. Cancer Res (2002) 1.13
Targeting the cell cycle for cancer therapy. Br J Cancer (2002) 1.12
Assignment of SV40-immortalized cells to more than one complementation group for immortalization. Exp Cell Res (1993) 1.10
Induction of senescence-like phenotypes by forced expression of hic-5, which encodes a novel LIM motif protein, in immortalized human fibroblasts. Mol Cell Biol (1997) 1.08
Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood (1998) 1.06
Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene (2007) 1.03
S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis. Carcinogenesis (2008) 1.00
The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene (1998) 1.00
Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest (2002) 1.00
Multiple pathways for the regulation of telomerase activity. Eur J Cancer (1997) 0.98
Glycolytic enzymes can modulate cellular life span. Cancer Res (2005) 3.78
PTEN, more than the AKT pathway. Carcinogenesis (2007) 2.70
Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem (2005) 2.31
Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol (2013) 1.84
CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene (2005) 1.63
Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. Cell Cycle (2011) 1.53
Spinophilin loss contributes to tumorigenesis in vivo. Cell Cycle (2011) 1.45
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther (2005) 1.32
Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol (2012) 1.31
Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res (2005) 1.30
Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation. Mol Cell Biol (2009) 1.20
The PIM family of serine/threonine kinases in cancer. Med Res Rev (2013) 1.17
Cell cycle deregulation: a common motif in cancer. Prog Cell Cycle Res (2003) 1.14
Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. J Cell Biochem (2005) 1.04
Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis (2006) 1.03
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J Biol Chem (2009) 1.03
Understanding FOXO, new views on old transcription factors. Curr Cancer Drug Targets (2010) 1.01
Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation. Cancer Res (2008) 0.97
Chemical genetic analysis of FOXO nuclear-cytoplasmic shuttling by using image-based cell screening. Chembiochem (2008) 0.97
Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res (2005) 0.96
An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays. Assay Drug Dev Technol (2007) 0.95
Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines. Mol Cancer Ther (2008) 0.94
Levels of p27(kip1) determine Aplidin sensitivity. Mol Cancer Ther (2007) 0.94
Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Lett (2010) 0.93
MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis (2007) 0.93
PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis (2008) 0.92
DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab (2013) 0.92
MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis (2007) 0.92
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem (2007) 0.91
Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. Dis Markers (2012) 0.90
Down-regulation of spinophilin in lung tumours contributes to tumourigenesis. J Pathol (2011) 0.89
Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS One (2010) 0.87
Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood (2007) 0.87
Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function. Carcinogenesis (2008) 0.87
MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival. PLoS One (2013) 0.86
Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma. Clin Cancer Res (2013) 0.86
Characterization of the p53 response to oncogene-induced senescence. PLoS One (2008) 0.86
The essential role of PIM kinases in sarcoma growth and bone invasion. Carcinogenesis (2012) 0.86
The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras. Carcinogenesis (2010) 0.86
Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators. BMC Cell Biol (2009) 0.86
Cellular senescence induced by p53-ras cooperation is independent of p21waf1 in murine embryo fibroblasts. J Cell Biochem (2004) 0.86
MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation. Carcinogenesis (2007) 0.86
Genetic modelling of the PTEN/AKT pathway in cancer research. Clin Transl Oncol (2008) 0.85
Overexpression of cyclin D1 inhibits TNF-induced growth arrest. J Cell Biochem (2003) 0.85
Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria. Anticancer Drugs (2005) 0.84
Influence of amine ligands on the aquation and cytotoxicity of trans-diamine platinum(II) anticancer complexes. Dalton Trans (2009) 0.84
Mouse models to decipher the PI3K signaling network in human cancer. Curr Mol Med (2009) 0.84
The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity. Dalton Trans (2010) 0.83
A dual-color fluorescence-based platform to identify selective inhibitors of Akt signaling. PLoS One (2008) 0.83
Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage. Int J Mol Sci (2013) 0.82
Inhibiting PI3K as a therapeutic strategy against cancer. Clin Transl Oncol (2009) 0.82
Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues. Mol Ther (2009) 0.81
PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome. BMC Cancer (2012) 0.81
The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine. Eur J Med Chem (2009) 0.80
Using cells devoid of RAS proteins as tools for drug discovery. Mol Carcinog (2009) 0.79
Structure-activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death. J Inorg Biochem (2006) 0.79
Bypassing cellular senescence by genetic screening tools. Clin Transl Oncol (2010) 0.78
Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia. PLoS One (2013) 0.78
New trans-platinum drugs with phosphines and amines as carrier ligands induce apoptosis in tumor cells resistant to cisplatin. J Med Chem (2007) 0.77
Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate. Carcinogenesis (2007) 0.77
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer (2014) 0.77
Cancer, senescence, and aging: translation from basic research to clinics. J Aging Res (2011) 0.76
EMX homeobox genes regulate microphthalmia and alter melanocyte biology. Exp Cell Res (2005) 0.76
Battling cancer on many fronts. Meeting on New Battlefields in Human Cancer--Attacking in Many Fronts. EMBO Rep (2008) 0.75
Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. Oncotarget (2016) 0.75
Influence of (hydroxymethyl)pyridine and pyridine-carboxylic acids, in trans-position to the isopropylamine and amine ligands, on the cytotoxicity of platinum complexes. Chem Biodivers (2008) 0.75
Between bench and bed side: PI3K inhibitors. Curr Mol Pharmacol (2010) 0.75
Non-neutral role of replicative senescence in tissue homeostasis and tumorigenesis. J Theor Biol (2004) 0.75
Identification of transcripts specific for physiological gene activation by platelet-derived growth factor (PDGF)-B in intact brain tissue. J Cell Biochem (2005) 0.75
Targeted search for anticancer drugs--CNIO cancer conference. 16-18 March, Madrid, Spain. IDrugs (2003) 0.75
The second generation of iodido complexes: trans-[PtI2(amine)(amine')] bearing different aliphatic amines. J Inorg Biochem (2013) 0.75
Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs. Chem Commun (Camb) (2013) 0.75
Adding more content to screening: reactivation of FOXO as a therapeutic strategy. Clin Transl Oncol (2009) 0.75